Tuesday, 12 September 2017
There could be a 20% upside in pharma largecaps in next 9 to 12 months: Dipan Mehta
Like you pointed out, Divi’s as a case of contract manufacturing stands to gain but we also think that the largecaps -- Sun, Dr Reddy, Lupin -- have a very strong pipeline and in the next three-four quarters the cash enhancement should be on the cards.
You can read more here: There could be a 20% upside in pharma largecaps in next 9 to 12 months: Dipan Mehta
Subscribe to:
Post Comments (Atom)
Life insurers earn more in Oct selling lesser policies
The 24-company Indian life insurance industry closed last month with new business of Rs 22,776.03 crore, up by 31.87 per cent over the prev...
No comments:
Post a Comment